DISCOVERY, PRE-CLINICAL, AND EARLY DEVELOPMENT (GLP & NON-GLP)
Developing a new drug from original idea to the launch of a finished product is a complex process which can take upwards of fifteen years and cost in excess of $1 billion. To remain competitive, research centers must find ways to streamline early processes to identify molecules which possess suitable characteristics. Increasingly this means optimizing business processes such as data capture, consolidation, and analytics across the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate molecule for clinical development.
Xybion’s Labwise platform is uniquely positioned, offers comprehensive business process enablement for today’s global laboratory enterprise, resulting in faster cycle times, reduced IT costs, and increased innovation. As a fully configurable, laboratory-centric business process management platform, Labwise enables critical business processes in preclinical and early development, such as (but not limited to):
- Material management workflows
- Equipment lifecycle management
- Quality and compliance management
- Document distribution and approvals, including SOPs, Work Instructions, Assay Development Methods,
- Process Chemistry Methods, and more
- Issue tracking for regulatory submission management purposes, supporting the creation of IND and NDA packages
For preclinical laboratories operating in both GLP and non-GLP environments, Xybion offers an end-to-
end solution that begins with data capture, through data consolidation and aggregation, into data analytics and reporting. By leveraging Labwise’s integration with the Pristima® and SavanteTM platforms, Xybion offers an out-of-the-box solution for preclinical study management, data capture, analytics, consolidation, and process compliance enablement.
Learn more about Xybion solutions for discovery, pre-clinical, and early development: